BTG Starts SOD Study In Premature Babies
Israeli firm Bio-Technology General has started a multicenter Phase IIIstudy of its recombinant superoxide dismutase (SOD) orphan drug product, OxSODrol, in premature newborns in the USA. OxSODrol will be administered intratracheally and its effects on the prevention of bronchopulmonary dysplasia (BPD) will be assessed.
There are about 50,000 premature infants born in the USA with respiratory syncytial virus infection, and 60% of these go on to develop BPD. Excess oxygen free radicals in the neonate lung have been implicated as a cause of the acute injury which can lead to permanent tissue damage. SOD is one of the enzymes which can degrade these free radicals, along with others such as peroxidase and catalase.
The study will look at the effect of prophylactic administration of OxSODrol on the development of BPD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze